atai Life Sciences
backs a broad derivative portfolio including DemeRx's noribogaine, an ibogaine metabolite cleared by the FDA for first-in-human testing as a non-psychoactive, lower-cardiotoxicity alternative to ibogaine,…
- Country
- Germany
- Ticker
- ATAI
venture-holding
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Psychedelic medicine & neuropsychiatric biologics | therapeutics-platforms | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.